FY2025 EPS Estimates for Zimmer Biomet Decreased by Analyst

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Equities researchers at Zacks Research cut their FY2025 EPS estimates for shares of Zimmer Biomet in a report released on Monday, June 16th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $7.92 for the year, down from their previous estimate of $7.95. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet's Q4 2025 earnings at $2.35 EPS, Q1 2026 earnings at $1.87 EPS, Q2 2026 earnings at $2.09 EPS and Q4 2026 earnings at $2.07 EPS.

A number of other research analysts have also recently weighed in on ZBH. The Goldman Sachs Group dropped their price objective on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. JPMorgan Chase & Co. lowered their target price on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Wells Fargo & Company lowered their target price on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Finally, Canaccord Genuity Group lowered their price objective on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research report on Monday, May 12th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $111.53.

Zimmer Biomet Trading Down 2.1%

Shares of ZBH stock opened at $90.22 on Wednesday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.46 and a current ratio of 2.44. The stock has a market capitalization of $17.85 billion, a P/E ratio of 19.96, a price-to-earnings-growth ratio of 2.13 and a beta of 0.72. The company has a 50 day moving average price of $96.01 and a 200 day moving average price of $103.21. Zimmer Biomet has a fifty-two week low of $89.22 and a fifty-two week high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The business had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. During the same period in the previous year, the firm posted $1.94 earnings per share. The company's revenue was up 1.1% on a year-over-year basis.

Institutional Trading of Zimmer Biomet

A number of large investors have recently made changes to their positions in ZBH. Garde Capital Inc. acquired a new stake in shares of Zimmer Biomet in the first quarter valued at approximately $29,000. Menard Financial Group LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth $30,000. Washington Trust Advisors Inc. acquired a new stake in Zimmer Biomet during the 1st quarter worth $30,000. Columbia River Financial Group LLC acquired a new stake in Zimmer Biomet during the 1st quarter worth $30,000. Finally, Accent Capital Management LLC acquired a new stake in shares of Zimmer Biomet during the first quarter worth about $35,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Sang Yi sold 1,000 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider now directly owns 20,424 shares of the company's stock, valued at $1,940,280. This represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.70% of the company's stock.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.06%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet's payout ratio is 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.